Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature
| Autor: | Vijayveer Bonthapally, Stephanie Sasse, John Radford, Pier Luigi Zinzani, O. Shonukan |
|---|---|
| Přispěvatelé: | P. L. Zinzani, S. Sasse, J. Radford, O. Shonukan, V. Bonthapally |
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Antibody-drug conjugate Immunoconjugates CD30 HL Refractory Recurrence Internal medicine hemic and lymphatic diseases medicine Humans Brentuximab vedotin Anaplastic large-cell lymphoma Brentuximab Vedotin business.industry Hematology medicine.disease Hodgkin Disease Lymphoma Tolerability Immunology Hodgkin lymphoma Lymphoma Large-Cell Anaplastic business medicine.drug |
| Zdroj: | Critical reviews in oncology/hematology. 95(3) |
| ISSN: | 1879-0461 |
| Popis: | Brentuximab vedotin was made available via a Named Patient Program (NPP) to non-US/Canadian patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL) until approval in their respective countries. We re-evaluated the efficacy and safety NPP data in a pooled analysis. Through a systematic literature review, 21 NPP publications were identified describing 14 cohorts (N=245). Among patients with a specified diagnosis, 207 had HL, 28 had ALCL, and one had CD30+ T-cell lymphoma (not specified). In cohorts reporting response, overall response and complete remission rates were 67\% and 26\%, respectively, in R/R HL, and 75\% and 74\%, respectively, in R/R ALCL. Incidences of grade 3/4 neurologic and hematologic toxicities were 6\% and 12\%, respectively; 5\% of patients discontinued because of toxicity. In real-world practice, response rates and tolerability to brentuximab vedotin are similar to those reported in the two pivotal phase 2 trials in these settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect